News

A real-world study shows benralizumab significantly reduced severe asthma exacerbations in older adults, with a 43.5% decrease in annual rates.

A study of 3 large US cohorts found a higher intake of butter was linked to greater mortality rates, while plant-based oil intake lowered total mortality.

Findings suggest cardiometabolic risk factors, diet, exercise, and social determinants of health are associated with HRQoL and fibrosis in MASLD.

In this video, part 5 of a 5-part series, panelists discuss emerging innovations in food allergy and anaphylaxis research poised to reshape clinical practice.

In this video, part 4 of a 5-part series, panelists discuss gaps in clinician education regarding food allergies and anaphylaxis.

In this video, part 3 of a 5-part series, panelists discuss on how needle-free epinephrine and evolving therapies are reshaping food allergy management.

In this video, part 2 of a 5-part series, panelists discuss unmet needs in pediatric food allergy research and clinical care.

In this video, part 1 of a 5-part series, panelists discuss on recent advancements in pediatric food allergy and anaphylaxis management.

Andrew Alexis, MD, MPH, highlights his ‘What’s New’ talk at AAD 2025 on new practices for treating pigmentary disorders such as vitiligo.

Tezepelumab significantly reduced nasal polyp severity in CRSwNP patients during the phase 3 WAYPOINT trial, lowering the need for surgery by 92%.

Pongdee also discussed the changing treatment landscape for indolent systemic mastocytosis and questions that will need to be answered in the field.

Patients with PBC and cirrhosis had a higher comorbidity burden and more acute-care events than those without cirrhosis.

The regulatory agency granted 510(k) clearance to Caristo Diagnostics' image analysis software to aid in coronary artery disease diagnosis.

Bernstein also discussed other unmet needs in the field and how his center is working to address them.

At AAAAI 2025, HCPLive spoke with Craig about recognizing and treating hereditary angioedemia.

Fonarow describes a revised classification of glucose levels that breaks down the normal range into lower and higher levels of associated cardiovascular risk.

With a new FDA goal date in June, ketamine is one step closer to receiving approval for anesthesia, sedation, pain, mental health, and neurological indications.

In this interview with Christopher Bunick, MD, PhD, at AAD 2025, he discusses his update given in a presentation regarding acne and rosacea treatments.

The Kidney Transplant Fast Track evaluation approach was associated with a higher likelihood of waitlisting and fewer disparities by race or ethnicity.

Lipworth shared findings from 2 studies that he presented data from at the AAAAI/WAO Joint Congress.

Mostaghimi highlights the major takeaways from his talk on alopecia areata therapies, the contents of which were presented at AAD 2025.

Topline data from the pivotal Launch-HTN and Advance-HTN trials met primary endpoints, supporting lorundrostat for uncontrolled or resistant hypertension.

Cianferoni discusses how pollen food allergy syndrome contributes to eosinophilic esophagitis (EoE) and potential management strategies.

The regulatory agency accepted the BLA's filing and assigned a target action date of August 31, 2025.

These data presented at AAD 2025 indicate sustained 2-year disease control in key hidradenitis suppurativa (HS) symptoms with bimekizumab-bkzx treatment.

At AAAAI 2025, Cianferoni described molecular mechanisms of pollen food allergy syndrome.

The pivotal trial showed superior weight loss to placebo at 68 weeks but fell short of ≥25% weight loss initially expected by Novo Nordisk.

Omalizumab-igec is approved in 2 formulations for the treatment of moderate to severe persistent asthma, CRSwNP, IgE-mediated food allergy, and CSU.